达利雷生现在在中国上市了吗？好购买吗？

Daliramin is a new type of orexin receptor antagonist that selectively blocks the binding of wake-promoting neuropeptides (orexins A and B) secreted by the hypothalamus to their receptors OX1R and OX2R, inhibiting the transmission of arousal signals, thereby reducing the excitability of the central nervous system and promoting the initiation and maintenance of sleep. Its accessibility in the Chinese market has attracted much attention. This article provides a detailed analysis of the drug's domestic listing status, actual purchase difficulty, and medical insurance reimbursement status, providing accurate information to patients in need.

Is DaliRasen now available in China?

The progress of registration and approval in China directly affects the accessibility of the drug to patients.

Drug Approval Status

As of now, DaliRasen has not yet received marketing approval from the China National Medical Products Administration, and formal domestic medical institutions cannot provide the drug.

Approval time forecast

According to the new drug approval process, if the company has submitted an application, it is expected to take 12-24 months to complete the approval. No public application information has been found yet.

Alternative drug situation

Other types of insomnia treatment drugs, such as benzodiazepines and non-benzodiazepine drugs, have been approved in China and can be used as temporary alternatives.

Patients can follow the official website of the Drug Evaluation Center of the State Food and Drug Administration to obtain the latest approval updates.

Is Dali Rayson good to buy?

Since it is not listed in China, there are certain difficulties and risks in obtaining Dali Rayson.

Formal purchasing channels

There are currently no legal sales channels in China. If patients need to use it, they can only obtain it through overseas purchase or cross-border medical services.

Cross-border purchasing methods

Including bringing back for overseas medical treatment, direct mail from international pharmacies and purchasing on cross-border medical platforms. These methods are all at your own risk for quality and transportation.

Purchase risk warning

Counterfeit products may appear on the market. When purchasing, you should check the drug batch number, packaging integrity and supplier qualifications.

It is recommended to check the authorized dealer information through the original manufacturer’s official website and choose reliable purchasing channels.

Is DaliRasen included in the national medical insurance?

The reimbursement situation of medical insurance directly affects the financial burden of patients.

Current status of the National Medical Insurance Drug List

DaliRasen is not included in the National Medical Insurance Drug List because it is not marketed in China. Patients are required to bear the full cost of treatment at their own expense.

Local medical insurance policies

The local supplementary medical insurance and Huimin Insurance have not yet included this drug in the coverage. Commercial insurance reimbursement depends on specific terms.

Possibility of future inclusion

If approved for marketing in the future, it is expected to be included in reimbursement after medical insurance negotiations, but the specific time and reimbursement ratio are still uncertain.

Patients may consider participating in formal clinical trials to obtain drug treatment opportunities under the supervision of doctors.